DOWNERS GROVE, Ill., Feb. 14, 2012 /PRNewswire-USNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announces it will fund a human clinical trial to assess a potential treatment for the rare genetic disorder, Angelman Syndrome (AS). The Minocycline in the Treatment of Angelman Syndrome study will examine if the off label administration of minocycline will alter the severity of symptoms associated with Angelman Syndrome. Minocycline, an FDA approved antibiotic, is traditionally used to treat bacterial infections in several organ systems.
The single arm open label trial will take place at the University of South Florida. Eligible participants must be between the ages of 4 to 12 years of age and have a molecularly confirmed diagnosis of Angelman Syndrome.
Paula Evans, Founder and Chairperson of FAST, stated, "There are currently no treatments for the cognitive, motor or behavioral deficits associated with Angelman Syndrome. The idea for testing FDA approved drugs in the AS mouse was born in FAST as a way to bring potential therapeutics to use with the greatest speed and efficiency. We could not be more pleased or excited that an FDA approved drug has shown promise in the AS mouse model and may potentially show improvements in children with AS."
"This study has the potential to play a much-needed role in improving the core symptoms of Angelman Syndrome and helping patients and families achieve an improved quality of life," said University of South Florida Neuroscientist Edwin Weeber, PhD.
"We are thrilled that we were able to go from testing minocycline in the AS mouse to human clinical trials within one year; a remarkably rapid time frame that speaks to the power of this approach," said Rebecca Burdine, PhD, Chief Science Officer for FAST. "We remain committed to supporting ongoing research to test additional FDA approved drugs for their potential therapeutic use in treating the sy
|SOURCE Foundation for Angelman Syndrome Therapeutics (FAST)|
Copyright©2010 PR Newswire.
All rights reserved